Neurofilament light chain (NfL) is a protein released when nerve fibers are injured. In people with multiple sclerosis (MS), a blood test can measure NfL to help estimate recent nerve-cell damage and may provide clues about disease activity or response to treatment. It cannot confirm MS or show the full picture on its own, so clinicians interpret it alongside symptoms, examination, MRI scans, and other results.
What is neurofilament light chain?
Neurofilament light chain, usually shortened to NfL, is a structural protein found inside nerve cells. It helps maintain the structure of axons, which are the long extensions that carry electrical signals between nerve cells and other parts of the body. When axons are damaged, NfL can be released into the surrounding fluid and eventually reach the bloodstream.
In multiple sclerosis, inflammation can damage nerve fibers in the brain and spinal cord. This damage may release NfL, making the protein a useful biological marker of injury to the nervous system. According to Cleveland Clinic's neurofilament light chain guidance, NfL can be measured in blood and cerebrospinal fluid, and its levels can provide information about nerve injury associated with MS.
NfL is not unique to multiple sclerosis. Other neurological conditions and injuries can also damage nerve fibers and increase NfL levels. Therefore, the result must be interpreted in the context of a person's health, medical history, and other findings.
How is NfL testing used in multiple sclerosis?
NfL testing can provide additional information about the activity of MS and how the disease responds to treatment. The test is particularly interesting because changes in NfL may reflect nerve injury even when a person has not noticed a new symptom. However, it does not measure every aspect of MS, and a result cannot reliably describe the full extent of disease activity by itself.
The Consortium of Multiple Sclerosis Centers (CMSC) describes NfL as a biomarker associated with MRI findings, relapse risk, measures of brain volume, and responses to disease-modifying treatment. These relationships make the test a potentially useful addition to routine MS monitoring, rather than a replacement for established assessments.
Monitoring disease activity
Higher NfL levels may be associated with active inflammation in the central nervous system. In people with MS, this can include periods associated with new or active lesions on magnetic resonance imaging (MRI) and clinical relapses. A rising result may therefore prompt a neurologist to review other information about disease activity and consider whether additional assessment is appropriate.
However, not every new MS lesion causes a detectable rise in blood NfL. Some people may have active MRI findings without an increase in the marker. NfL can also rise after other types of nerve injury, so a higher result does not establish that MS is becoming more active.
Assessing the response to treatment
Some disease-modifying therapies used for MS reduce inflammatory activity and are associated with lower blood NfL levels. Following changes over time may help a healthcare professional assess whether a treatment is having the expected biological effect. NfL may also provide additional information between scheduled MRI scans.
A decrease in NfL does not automatically prove that treatment is working well in every respect. Similarly, an increase does not necessarily mean that a medication has failed. Treatment decisions require consideration of clinical symptoms, examination findings, MRI results, treatment history, and other relevant information.
What does a high or rising NfL level mean?
A higher-than-expected NfL result indicates that more of this protein has been detected in the sample than expected for the comparison being used. In someone with MS, this may reflect recent or ongoing nerve-cell injury. However, the result cannot identify the exact location, cause, or extent of that injury.
When a result is higher than a person's previous measurements, a neurologist may consider whether there has been a change in disease activity, whether the timing of the test is relevant, and whether another condition could explain the change. The meaning of the result depends partly on the person's baseline level, age, other health conditions, and the laboratory method used.
A single measurement is generally less informative than a carefully interpreted pattern over time. Even then, trends must be considered alongside other findings because NfL levels do not capture every type of MS-related injury or progression.
Why timing matters
NfL levels do not necessarily rise at the same time that nerve injury begins. In some people, the increase may become measurable weeks after inflammatory activity first appears on MRI. This delay means that a blood result reflects a biological response over time rather than providing a real-time picture of the nervous system.
A Cleveland Clinic report on research involving people with MS explains that blood NfL elevations may lag behind the appearance of active MRI lesions, and many people with those lesions do not show a corresponding rise in NfL. The findings support using serum NfL as a supplement to MRI monitoring, not as a substitute for imaging or clinical evaluation.
Can NfL testing diagnose multiple sclerosis?
No. NfL is a marker of nerve injury, not a test that identifies MS specifically. Its level may be higher in several neurological conditions, and a result within an expected range does not rule out MS or exclude current disease activity.
MS diagnosis relies on an overall assessment of the clinical history, neurological examination, MRI findings, and other investigations when appropriate. NfL may contribute useful information in selected circumstances, but it cannot independently establish or exclude the diagnosis.
There is also no single NfL threshold that can be applied to everyone to determine whether MS is active. Different laboratory methods can produce different results, and the expected level depends on individual characteristics. A value should therefore be interpreted using the laboratory's method and the clinical context, rather than a universal cutoff.
What factors can affect NfL levels?
Multiple sclerosis is only one possible influence on NfL. A healthcare professional may consider several factors when explaining a result, particularly when it does not match the person's symptoms, MRI findings, or previous measurements.
- Age: NfL levels tend to increase with age, so age-aware interpretation is important.
- Kidney function: Reduced kidney function can be associated with higher measured blood NfL levels.
- Other health conditions: Conditions such as diabetes may affect NfL levels and should be considered when interpreting results.
- Other neurological injury: Stroke, trauma, and other disorders that affect nerve cells can also increase NfL.
- Laboratory method: Different testing platforms may produce different measurements, making some results difficult to compare directly.
- Timing of testing: NfL may rise after the initial injury, so the interval between an event and the blood draw can influence what the result shows.
A clinical review available through the U.S. National Library of Medicine's PubMed database discusses the practical uses and limitations of serum NfL monitoring in MS, including the importance of considering factors that affect the reliability of measurements before using them to guide care.
How is neurofilament light chain measured?
In MS monitoring, NfL is commonly measured using a blood sample. The laboratory may analyze serum or plasma, which are the liquid portions of blood. Highly sensitive laboratory methods can measure the small amounts of NfL normally present in these samples. NfL can also be measured in cerebrospinal fluid, the fluid surrounding the brain and spinal cord, when that information is relevant to a clinical assessment.
The testing process depends on the type of sample and the laboratory's procedures. Whether NfL testing is available and useful for an individual depends on the clinical setting and the question the healthcare professional is trying to answer. It is not necessary to interpret the test as a stand-alone measure of MS activity.
How do doctors interpret NfL alongside MRI and other findings?
NfL and MRI provide different types of information. NfL reflects a protein released in response to nerve-cell injury, while MRI can show the location and characteristics of lesions in the brain and spinal cord. Clinical examinations and the person's history help clarify whether there are changes in function or symptoms.
A 2024 clinical guidance paper published in eBioMedicine on the use of NfL in MS management supports considering the marker alongside MRI and clinical measures. This combined approach helps clinicians assess findings that may not be fully explained by any one test.
For example, a rising NfL level with new MRI lesions may support concern about increased inflammatory activity. A stable result does not necessarily exclude active disease, and a higher result without new MRI changes may require a broader review. The significance of such patterns depends on the individual clinical situation.
Does NfL show whether multiple sclerosis is progressing?
NfL can provide information about nerve injury associated with inflammatory activity, but its relationship with long-term disability progression is more complicated. Research has found associations between higher NfL and some later outcomes, yet these findings do not mean that a single measurement can predict an individual's future level of disability.
In progressive MS, disability may worsen even when there is little obvious inflammatory activity on MRI or during clinical relapses. Blood NfL does not reliably capture every process involved in this type of progression. A relatively low or stable level should therefore not be taken as proof that the disease is not progressing.
Neurologists assess progression through changes in function over time, clinical examinations, relevant imaging, and other findings. NfL may add context, but it cannot replace these assessments.
What should you discuss with your neurologist about an NfL result?
If an NfL result is part of your MS care, it may help to ask how it compares with your earlier measurements and what other findings are relevant to its interpretation. Understanding why the test was ordered can also clarify whether the aim is to monitor disease activity, assess a treatment response, or explore a change that needs further evaluation.
Useful questions include whether the laboratory used the same testing method as before, whether age and other health conditions could influence the measurement, and whether the result changes the plan for clinical follow-up or MRI. Do not stop or change a prescribed disease-modifying treatment solely because of an NfL result. Discuss any concerning or unexpected findings with the healthcare professional managing your MS.
Overall, neurofilament light chain is a promising tool for understanding nerve injury in multiple sclerosis. Its greatest value comes from interpreting the result over time and alongside clinical assessment and MRI, rather than relying on one number to describe the disease.